Recent Research Analysts’ Ratings Updates for Amgen (AMGN)

Several analysts have recently updated their ratings and price targets for Amgen (NASDAQ: AMGN):

• 2/21/2026 – Amgen was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/20/2026 – Amgen is now covered by Barclays PLC. They set an “equal weight” rating and a $350.00 price target on the stock.
• 2/19/2026 – Amgen was given a new $185.00 price target by Barclays PLC. They now have an “equal weight” rating on the stock.
• 2/19/2026 – Amgen had its price target raised by Wells Fargo & Company from $325.00 to $375.00. They now have an “equal weight” rating on the stock.
• 2/19/2026 – Amgen was upgraded by Barclays PLC to “hold”.
• 2/18/2026 – Amgen had its price target raised by Piper Sandler from $381.00 to $432.00. They now have an “overweight” rating on the stock.
• 2/18/2026 – Amgen had its price target raised by Rothschild & Co Redburn from $180.00 to $200.00. They now have a “sell” rating on the stock.
• 2/12/2026 – Amgen was downgraded by Freedom Capital from “strong-buy” to “hold”.
• 2/10/2026 – Amgen had its price target raised by Mizuho from $280.00 to $295.00. They now have an “outperform” rating on the stock.
• 2/10/2026 – Amgen had its price target raised by Daiwa Securities Group Inc. from $370.00 to $410.00. They now have an “outperform” rating on the stock.
• 2/7/2026 – Amgen was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 2/6/2026 – Amgen had its price target raised by Argus from $360.00 to $400.00. They now have a “buy” rating on the stock.
• 2/6/2026 – Amgen had its price target raised by Guggenheim from $305.00 to $347.00. They now have a “neutral” rating on the stock.
• 2/5/2026 – Amgen had its price target raised by Deutsche Bank Aktiengesellschaft from $285.00 to $295.00. They now have a “hold” rating on the stock.
• 2/4/2026 – Amgen had its “buy” rating reaffirmed by TD Cowen.
• 2/4/2026 – Amgen had its price target raised by Citigroup Inc. from $315.00 to $345.00. They now have a “neutral” rating on the stock.
• 2/4/2026 – Amgen had its price target raised by Cantor Fitzgerald from $315.00 to $350.00. They now have a “neutral” rating on the stock.
• 2/4/2026 – Amgen had its price target raised by The Goldman Sachs Group, Inc. from $403.00 to $415.00. They now have a “buy” rating on the stock.
• 2/4/2026 – Amgen had its price target raised by Morgan Stanley from $304.00 to $309.00. They now have an “equal weight” rating on the stock.
• 2/4/2026 – Amgen had its price target raised by Royal Bank Of Canada from $335.00 to $360.00. They now have an “outperform” rating on the stock.
• 2/4/2026 – Amgen had its price target raised by Leerink Partners from $305.00 to $355.00. They now have an “outperform” rating on the stock.
• 1/29/2026 – Amgen was given a new $400.00 price target by Oppenheimer Holdings, Inc.. They now have an “outperform” rating on the stock.
• 1/26/2026 – Amgen had its price target raised by UBS Group AG from $380.00 to $390.00. They now have a “buy” rating on the stock.
• 1/20/2026 – Amgen was downgraded by Sanford C. Bernstein from “outperform” to “market perform”. They now have a $335.00 price target on the stock.
• 1/8/2026 – Amgen had its price target raised by Royal Bank Of Canada from $330.00 to $335.00. They now have an “outperform” rating on the stock.
• 1/8/2026 – Amgen had its price target raised by The Goldman Sachs Group, Inc. from $400.00 to $403.00. They now have a “buy” rating on the stock.
• 1/8/2026 – Amgen had its price target raised by Truist Financial Corporation from $318.00 to $319.00. They now have a “hold” rating on the stock.
• 1/7/2026 – Amgen was upgraded by UBS Group AG to “strong-buy”.
• 1/6/2026 – Amgen is now covered by UBS Group AG. They set a “buy” rating and a $380.00 price target on the stock.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is currently 70.84%.

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.